JCLA:重组链霉亲和蛋白融合蛋白作为快速检测丙型肝炎病毒感染的信号转导蛋白

2019-07-15 gladiator 网络

丙型肝炎病毒(HCV)感染得早期诊断对该病的治疗非常重要。因此,研制灵敏、特异的快速检测方法对该病的诊断也具有重要意义。在这里,我们描述了一种很有前景的方法,使用金‐标记的链霉亲和蛋白融合蛋白作为新的信号报告蛋白,用于快速检测丙型肝炎病毒感染。 在表达载体pMAL‐5CX和pET28中克隆了与大肠杆菌麦芽糖结合蛋白(MBP)或部分细菌翻译起始因子2融合的链霉亲和素重组基因,并在适当的大肠杆菌

丙型肝炎病毒(HCV)感染得早期诊断对该病的治疗非常重要。因此,研制灵敏、特异的快速检测方法对该病的诊断也具有重要意义。在这里,我们描述了一种很有前景的方法,使用金‐标记的链霉亲和蛋白融合蛋白作为新的信号报告蛋白,用于快速检测丙型肝炎病毒感染

在表达载体pMAL5CXpET28中克隆了与大肠杆菌麦芽糖结合蛋白(MBP)或部分细菌翻译起始因子2融合的链霉亲和素重组基因,并在适当的大肠杆菌宿主菌株中转化。基因诱导和链霉亲和素融合蛋白,并分别命名为MSTVIF-STV,亲和色谱法纯化纯度90%以上。采用酶联免疫吸附试验(ELISA)检测MSTVIFSTV的生物素结合活性。MSTV被标记为胶体金纳米颗粒,并作为信号报告,将其用于开发一种基于横向流动的快速测试,用于检测人体血液样本中的抗HCV抗体。

研究发现,MSTV与商业链霉亲和素相比,具有略高的生物素‐结合活性和类似的结合特异性。金‐标记的MSTV与生物素分子特异性结合,以剂量响应的方式固定在快速测试条带上,并成功用于检测丙型肝炎病毒感染患者血清样本中的丙型肝炎病毒抗体。快速检测显示出比金‐标记的商业NeutrAvidin更高的检测灵敏度。

我们的研究结果表明,金‐标记的MSTV是一种有前途的快速检测丙型肝炎病毒感染以及其他病毒感染的试剂。

原始出处:

Shengliang Zhou , Shinian Cao, Recombinant streptavidin fusion proteins as signal reporters in rapid test of human hepatitis C virus infection

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1987948, encodeId=8d7d198e948ad, content=<a href='/topic/show?id=00d88886e5e' target=_blank style='color:#2F92EE;'>#融合蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88867, encryptionId=00d88886e5e, topicName=融合蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e4137, createdName=meichuangyi, createdTime=Mon Dec 02 04:37:00 CST 2019, time=2019-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274672, encodeId=154d12e467247, content=<a href='/topic/show?id=30872089e03' target=_blank style='color:#2F92EE;'>#丙型肝炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20897, encryptionId=30872089e03, topicName=丙型肝炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f503121, createdName=zjubiostat, createdTime=Wed Jul 17 13:37:00 CST 2019, time=2019-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429565, encodeId=ea591429565a6, content=<a href='/topic/show?id=534e2090181' target=_blank style='color:#2F92EE;'>#丙型肝炎病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20901, encryptionId=534e2090181, topicName=丙型肝炎病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a26a4213133, createdName=anan, createdTime=Wed Jul 17 13:37:00 CST 2019, time=2019-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525510, encodeId=54ed152551059, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88858, encryptionId=08548885835, topicName=融合)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08a911636812, createdName=licz0427, createdTime=Wed Jul 17 13:37:00 CST 2019, time=2019-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369759, encodeId=4141369e591c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Tue Jul 16 09:24:33 CST 2019, time=2019-07-16, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1987948, encodeId=8d7d198e948ad, content=<a href='/topic/show?id=00d88886e5e' target=_blank style='color:#2F92EE;'>#融合蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88867, encryptionId=00d88886e5e, topicName=融合蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e4137, createdName=meichuangyi, createdTime=Mon Dec 02 04:37:00 CST 2019, time=2019-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274672, encodeId=154d12e467247, content=<a href='/topic/show?id=30872089e03' target=_blank style='color:#2F92EE;'>#丙型肝炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20897, encryptionId=30872089e03, topicName=丙型肝炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f503121, createdName=zjubiostat, createdTime=Wed Jul 17 13:37:00 CST 2019, time=2019-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429565, encodeId=ea591429565a6, content=<a href='/topic/show?id=534e2090181' target=_blank style='color:#2F92EE;'>#丙型肝炎病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20901, encryptionId=534e2090181, topicName=丙型肝炎病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a26a4213133, createdName=anan, createdTime=Wed Jul 17 13:37:00 CST 2019, time=2019-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525510, encodeId=54ed152551059, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88858, encryptionId=08548885835, topicName=融合)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08a911636812, createdName=licz0427, createdTime=Wed Jul 17 13:37:00 CST 2019, time=2019-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369759, encodeId=4141369e591c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Tue Jul 16 09:24:33 CST 2019, time=2019-07-16, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1987948, encodeId=8d7d198e948ad, content=<a href='/topic/show?id=00d88886e5e' target=_blank style='color:#2F92EE;'>#融合蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88867, encryptionId=00d88886e5e, topicName=融合蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e4137, createdName=meichuangyi, createdTime=Mon Dec 02 04:37:00 CST 2019, time=2019-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274672, encodeId=154d12e467247, content=<a href='/topic/show?id=30872089e03' target=_blank style='color:#2F92EE;'>#丙型肝炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20897, encryptionId=30872089e03, topicName=丙型肝炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f503121, createdName=zjubiostat, createdTime=Wed Jul 17 13:37:00 CST 2019, time=2019-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429565, encodeId=ea591429565a6, content=<a href='/topic/show?id=534e2090181' target=_blank style='color:#2F92EE;'>#丙型肝炎病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20901, encryptionId=534e2090181, topicName=丙型肝炎病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a26a4213133, createdName=anan, createdTime=Wed Jul 17 13:37:00 CST 2019, time=2019-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525510, encodeId=54ed152551059, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88858, encryptionId=08548885835, topicName=融合)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08a911636812, createdName=licz0427, createdTime=Wed Jul 17 13:37:00 CST 2019, time=2019-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369759, encodeId=4141369e591c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Tue Jul 16 09:24:33 CST 2019, time=2019-07-16, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1987948, encodeId=8d7d198e948ad, content=<a href='/topic/show?id=00d88886e5e' target=_blank style='color:#2F92EE;'>#融合蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88867, encryptionId=00d88886e5e, topicName=融合蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e4137, createdName=meichuangyi, createdTime=Mon Dec 02 04:37:00 CST 2019, time=2019-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274672, encodeId=154d12e467247, content=<a href='/topic/show?id=30872089e03' target=_blank style='color:#2F92EE;'>#丙型肝炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20897, encryptionId=30872089e03, topicName=丙型肝炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f503121, createdName=zjubiostat, createdTime=Wed Jul 17 13:37:00 CST 2019, time=2019-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429565, encodeId=ea591429565a6, content=<a href='/topic/show?id=534e2090181' target=_blank style='color:#2F92EE;'>#丙型肝炎病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20901, encryptionId=534e2090181, topicName=丙型肝炎病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a26a4213133, createdName=anan, createdTime=Wed Jul 17 13:37:00 CST 2019, time=2019-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525510, encodeId=54ed152551059, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88858, encryptionId=08548885835, topicName=融合)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08a911636812, createdName=licz0427, createdTime=Wed Jul 17 13:37:00 CST 2019, time=2019-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369759, encodeId=4141369e591c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Tue Jul 16 09:24:33 CST 2019, time=2019-07-16, status=1, ipAttribution=)]
    2019-07-17 licz0427
  5. [GetPortalCommentsPageByObjectIdResponse(id=1987948, encodeId=8d7d198e948ad, content=<a href='/topic/show?id=00d88886e5e' target=_blank style='color:#2F92EE;'>#融合蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88867, encryptionId=00d88886e5e, topicName=融合蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e4137, createdName=meichuangyi, createdTime=Mon Dec 02 04:37:00 CST 2019, time=2019-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274672, encodeId=154d12e467247, content=<a href='/topic/show?id=30872089e03' target=_blank style='color:#2F92EE;'>#丙型肝炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20897, encryptionId=30872089e03, topicName=丙型肝炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f503121, createdName=zjubiostat, createdTime=Wed Jul 17 13:37:00 CST 2019, time=2019-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429565, encodeId=ea591429565a6, content=<a href='/topic/show?id=534e2090181' target=_blank style='color:#2F92EE;'>#丙型肝炎病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20901, encryptionId=534e2090181, topicName=丙型肝炎病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a26a4213133, createdName=anan, createdTime=Wed Jul 17 13:37:00 CST 2019, time=2019-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525510, encodeId=54ed152551059, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88858, encryptionId=08548885835, topicName=融合)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08a911636812, createdName=licz0427, createdTime=Wed Jul 17 13:37:00 CST 2019, time=2019-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369759, encodeId=4141369e591c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Tue Jul 16 09:24:33 CST 2019, time=2019-07-16, status=1, ipAttribution=)]
    2019-07-16 phoebeyan520

    学习了

    0

相关资讯

JCLA:不同基因型丙型肝炎病毒RNA与核心抗原的相关性?

本研究的目的分析不同基因型丙型肝炎病毒(HCV) RNA与HCV核心抗原(HCV cAg)的相关性。

KIDNEY INT:直接作用抗病毒治疗可减缓丙型肝炎病毒感染和慢性肾病患者的肾功能下降

由此可见,用于丙型肝炎病毒感染的直接作用抗病毒疗法可以减缓慢性肾病的进展。

2019逆转录病毒和机会性感染会议CROI报道:感染HCV后接受直接抗病毒药物治疗的患者患糖尿病的风险降低

2019年逆转录病毒和机会性感染会议(CROI)上发布,回顾性研究结果显示,感染丙型肝炎病毒HCV后治疗过的患者患糖尿病的风险降低,特别是通过直接抗病毒方案清除感染的患者患病率更低。

CCLM:比较两种丙型肝炎病毒基因分型的方法

丙型肝炎病毒(HCV)基因型可以作为治疗的预测指标。研究人员依次评估了两种核酸扩增试验(NAATs)和一种HCV基因型的血清学检测方法,包括Abbott RealTi me基因型II(RealTi me II),GeneMatrix限制性片段质量多态性(RFM)和Sysmex HISCL HCV Gr(HISCL Gr )。研究人员用三个检测方法检查了281个临床样本,使用HCV基因型性能亚组PH

Clin J Am Soc Nephro:新药Sofosbuvir:丙型肝炎治疗在肾病患者中

一项新的研究表明,直接作用的抗病毒治疗在慢性肾脏疾病(CKD)和丙型肝炎病毒(HCV)感染患者中是安全有效的。美国肾脏病学杂志(CJASN)即将出版的研究报告也发现,治疗可能有助于改善一些患者的肾功能。

2018美国肝脏会议:丙型肝炎病毒感染的器官被认为对移植安全

导语 一项新的研究显示,直接作用的抗病毒药物可以使感染丙型肝炎的器官移植到没有病毒的受者身上。